相关实验视频
Updated: Jun 10, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.5K
第三代抗凝剂:XI,XII和XIII因子抑制剂
Sudesh Prajapathi1, Akshyaya Pradhan2, Aditi Mohta3
1Department of Cardiology, King George's Medical University, Shahmina Road, Chowk, Lucknow, Uttar Pradesh, 226003, India.
概括
针对XIa,XIIa和XIIIa因子的新型抗凝剂有望预防血栓栓塞事件,其出血风险可能比目前的治疗方法更低. 需要进一步的研究来确定它们在人类中的长期疗效和安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 心血管医学 心血管医学
背景情况:
- 血栓塞栓事件导致全球显著的死亡率,需要有效的抗凝策略.
- 目前的抗凝剂,如肝素和维生素K对抗剂,以及新的直接口服抗凝剂,都会带来出血的风险.
- 针对凝血因子XIa,XIIa和XIIIa的新型药物正在调查中,以提高安全性.
研究的目的:
- 审查和整合新型抗凝血药物临床试验的研究结果.
- 评估针对凝血因子XIa,XIIa和XIIIa的抑制剂的疗效和安全性.
主要方法:
- 对FXI,FXII和FXIII抑制剂发表的临床试验数据的审查.
- 对降低血栓栓塞事件的疗效和在出血风险方面安全性的分析.
主要成果:
- 在第2期研究中,XI因子抑制剂在减少静脉瘤发病率方面表现出优于埃诺沙巴林的优势,并具有更好的安全性.
- 动物研究表明,XII因子抑制剂可能降低出血风险.
- 实验室研究表明,XIII因子的抑制提供了强大的抗血栓作用,降低了出血风险.
结论:
- FXI抑制剂需要更大,更强大的研究来确认它们在预防高风险患者的动脉和静脉血栓栓塞事件中的作用.
- 对FXII和FXIII抑制剂的早期发现是有希望的,但需要进一步的人体研究来确定治疗疗效和安全性.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
633
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
633
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
480
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
480
Clot Retraction and Fibrinolysis
4.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.5K
Extrinsic and Intrinsic Pathways of Hemostasis
6.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.1K

